Rosiglitazone also promotes the redistribution of fat in the body, causing visceral fat to shift under the skin, which may be related to the effect of increasing insulin sensitivity, as well as improving the beta-cell function of the pancreatic islets and treating fatty liver and obesity in combination with diabetes [47]. Here, INS is linked to obesity due to melanocortin 4 receptor deficiency.